Youn H Sheen1,2, Sarah Kizilbash1,3, Eell Ryoo1,4, Chung-Il Wi1, Miguel Park5, Roshini S Abraham6, Euijung Ryu7, Rohit Divekar5, Young Juhn8. 1. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Pediatrics, CHA University School of Medicine, Seoul, Korea. 3. Department of Pediatrics, School of Medicine, University of Minnesota, Twin Cities, MN, USA. 4. Department of Pediatrics, Gil Hospital, Gachon University, Incheon, Korea. 5. Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA. 6. Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 7. Department of Health Sciences and Research, Mayo Clinic, Rochester, MN, USA. 8. Department of Pediatric and Adolescent Medicine/Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract
Objective: Asthma poses an increased risk for serious pneumococcal disease, but little is known about the influence of asthma status on the 23-valent serotype-specific pneumococcal antibody response. We examined differences in antibody titers between pre- and post-vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in relation to asthma status. Methods: Asthma status was retrospectively ascertained by the Predetermined Asthma Criteria in an existing vaccine cohort through comprehensive medical record review. Twenty-three serotype-specific pneumococcal antibody titers measured at baseline and 4-6 weeks post-vaccination were analyzed. Vaccine responses to PPSV-23 were calculated from pre- to post-vaccine titers for each of the serotypes. Results: Of the 64 eligible and enrolled subjects, 18 (28%) had asthma. Controls (i.e., subjects without asthma) demonstrated a statistically significant fold change response compared to their baseline for all serotypes, while those with asthma did not mount a significant response to serotypes 7F, 22F, and 23F. The overall vaccine response as measured by fold change over baseline was lower in subjects with asthma than controls. Conclusions: Poorer humoral immune responses to PPSV-23 as measured by fold change were more likely to be observed in subjects with asthma compared to controls. We recommend the consideration of asthma status when interpreting vaccine response for immune competence workup through larger studies. Further studies are warranted to replicate these findings.
Objective: Asthma poses an increased risk for serious pneumococcal disease, but little is known about the influence of asthma status on the 23-valent serotype-specific pneumococcal antibody response. We examined differences in antibody titers between pre- and post-vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV-23) in relation to asthma status. Methods:Asthma status was retrospectively ascertained by the Predetermined Asthma Criteria in an existing vaccine cohort through comprehensive medical record review. Twenty-three serotype-specific pneumococcal antibody titers measured at baseline and 4-6 weeks post-vaccination were analyzed. Vaccine responses to PPSV-23 were calculated from pre- to post-vaccine titers for each of the serotypes. Results: Of the 64 eligible and enrolled subjects, 18 (28%) had asthma. Controls (i.e., subjects without asthma) demonstrated a statistically significant fold change response compared to their baseline for all serotypes, while those with asthma did not mount a significant response to serotypes 7F, 22F, and 23F. The overall vaccine response as measured by fold change over baseline was lower in subjects with asthma than controls. Conclusions: Poorer humoral immune responses to PPSV-23 as measured by fold change were more likely to be observed in subjects with asthma compared to controls. We recommend the consideration of asthma status when interpreting vaccine response for immune competence workup through larger studies. Further studies are warranted to replicate these findings.
Authors: Y J Juhn; H Kita; L A Lee; R W Smith; S M Bagniewski; A L Weaver; V S Pankratz; R M Jacobson; G A Poland Journal: Tissue Antigens Date: 2007-01
Authors: Young J Juhn; Hirohito Kita; Linda A Lee; Rebecca J Swanson; Ryan Smith; Stephanie M Bagniewski; Amy L Weaver; V Shane Pankratz; Robert M Jacobson; Gregory A Poland Journal: Ann Allergy Asthma Immunol Date: 2006-10 Impact factor: 6.347
Authors: Ji A Jung; Hirohito Kita; Ravneet Dhillon; Robert M Jacobson; Moon H Nahm; Miguel Park; Constantine Tsigrelis; Young J Juhn Journal: Postgrad Med Date: 2010-09 Impact factor: 3.840
Authors: Jordan S Orange; Mark Ballow; E Richard Stiehm; Zuhair K Ballas; Javier Chinen; Maite De La Morena; Dinakantha Kumararatne; Terry O Harville; Paul Hesterberg; Majed Koleilat; Sean McGhee; Elena E Perez; Jason Raasch; Rebecca Scherzer; Harry Schroeder; Christine Seroogy; Aarnoud Huissoon; Ricardo U Sorensen; Rohit Katial Journal: J Allergy Clin Immunol Date: 2012-09 Impact factor: 10.793
Authors: H J Lee; J H Kang; J Henrichsen; H B Konradsen; S H Jang; H Y Shin; H S Ahn; Y Choi; L Hessel; S W Nam Journal: Vaccine Date: 1995-11 Impact factor: 3.641
Authors: Mady Hornig; José G Montoya; Nancy G Klimas; Susan Levine; Donna Felsenstein; Lucinda Bateman; Daniel L Peterson; C Gunnar Gottschalk; Andrew F Schultz; Xiaoyu Che; Meredith L Eddy; Anthony L Komaroff; W Ian Lipkin Journal: Sci Adv Date: 2015-02 Impact factor: 14.136
Authors: Zabrina L Brumme; Francis Mwimanzi; Hope R Lapointe; Peter K Cheung; Yurou Sang; Maggie C Duncan; Fatima Yaseen; Olga Agafitei; Siobhan Ennis; Kurtis Ng; Simran Basra; Li Yi Lim; Rebecca Kalikawe; Sarah Speckmaier; Nadia Moran-Garcia; Landon Young; Hesham Ali; Bruce Ganase; Gisele Umviligihozo; F Harrison Omondi; Kieran Atkinson; Hanwei Sudderuddin; Junine Toy; Paul Sereda; Laura Burns; Cecilia T Costiniuk; Curtis Cooper; Aslam H Anis; Victor Leung; Daniel Holmes; Mari L DeMarco; Janet Simons; Malcolm Hedgcock; Marc G Romney; Rolando Barrios; Silvia Guillemi; Chanson J Brumme; Ralph Pantophlet; Julio S G Montaner; Masahiro Niikura; Marianne Harris; Mark Hull; Mark A Brockman Journal: NPJ Vaccines Date: 2022-02-28 Impact factor: 9.399